Detalhe da pesquisa
1.
Urelumab alone or in combination with rituximab in patients with relapsed or refractory B-cell lymphoma.
Am J Hematol
; 95(5): 510-520, 2020 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-32052473
2.
A phase 2, randomized trial evaluating the combination of dalantercept plus axitinib in patients with advanced clear cell renal cell carcinoma.
Cancer
; 125(14): 2400-2408, 2019 07 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-30951193
3.
NCI 8628: A randomized phase 2 study of ziv-aflibercept and high-dose interleukin 2 or high-dose interleukin 2 alone for inoperable stage III or IV melanoma.
Cancer
; 124(22): 4332-4341, 2018 11 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-30303516
4.
Sequential administration of nivolumab and ipilimumab with a planned switch in patients with advanced melanoma (CheckMate 064): an open-label, randomised, phase 2 trial.
Lancet Oncol
; 17(7): 943-955, 2016 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-27269740
5.
Everolimus versus sunitinib for patients with metastatic non-clear cell renal cell carcinoma (ASPEN): a multicentre, open-label, randomised phase 2 trial.
Lancet Oncol
; 17(3): 378-388, 2016 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-26794930
6.
Contemporary experience with high-dose interleukin-2 therapy and impact on survival in patients with metastatic melanoma and metastatic renal cell carcinoma.
Cancer Immunol Immunother
; 65(12): 1533-1544, 2016 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-27714434
7.
Discordancy in BRAF mutations among primary and metastatic melanoma lesions: clinical implications for targeted therapy.
Mod Pathol
; 28(4): 480-6, 2015 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-25376477
8.
Combination of vemurafenib and cobimetinib in patients with advanced BRAF(V600)-mutated melanoma: a phase 1b study.
Lancet Oncol
; 15(9): 954-65, 2014 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-25037139
9.
Delivery of progenitors to the thymus limits T-lineage reconstitution after bone marrow transplantation.
Blood
; 118(7): 1962-70, 2011 Aug 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-21659540
10.
Foretinib (XL880): c-MET inhibitor with activity in papillary renal cell cancer.
Curr Oncol Rep
; 15(2): 83-90, 2013 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-23408121
11.
Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial.
Lancet Oncol
; 13(5): 459-65, 2012 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-22456429
12.
Talimogene laherparepvec in combination with ipilimumab versus ipilimumab alone for advanced melanoma: 5-year final analysis of a multicenter, randomized, open-label, phase II trial.
J Immunother Cancer
; 11(5)2023 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-37142291
13.
Combination Dabrafenib and Trametinib Versus Combination Nivolumab and Ipilimumab for Patients With Advanced BRAF-Mutant Melanoma: The DREAMseq Trial-ECOG-ACRIN EA6134.
J Clin Oncol
; 41(2): 186-197, 2023 01 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-36166727
14.
Safety profile and pharmacokinetic analyses of the anti-CTLA4 antibody tremelimumab administered as a one hour infusion.
J Transl Med
; 10: 236, 2012 Nov 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-23171508
15.
CCR7 and CCR9 together recruit hematopoietic progenitors to the adult thymus.
Blood
; 115(10): 1897-905, 2010 Mar 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-19965655
16.
A phase II study of 2-methoxyestradiol nanocrystal colloidal dispersion alone and in combination with sunitinib malate in patients with metastatic renal cell carcinoma progressing on sunitinib malate.
Invest New Drugs
; 30(2): 794-802, 2012 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-21174224
17.
Long-term progression-free survival of patients with metastatic melanoma or renal cell carcinoma following high-dose interleukin-2.
J Investig Med
; 2021 Feb 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-33542072
18.
Tissue based biomarkers in non-clear cell RCC: Correlative analysis from the ASPEN clinical trial.
Kidney Cancer J
; 19(3): 64-72, 2021 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-34765076
19.
Angiokines Associated with Targeted Therapy Outcomes in Patients with Non-Clear Cell Renal Cell Carcinoma.
Clin Cancer Res
; 27(12): 3317-3328, 2021 06 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-33593885
20.
Phase Ib/II Clinical Trial of Pembrolizumab With Bevacizumab for Metastatic Renal Cell Carcinoma: BTCRC-GU14-003.
J Clin Oncol
; 38(11): 1138-1145, 2020 04 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-32097091